Open AccessAvailability of research articles for the public during pandemic - a case study
Author(s) -
Augustine Joshua Devasahayam
Publication year - 2020
Publication title -
liber quarterly the journal of the association of european research libraries
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.392
H-Index - 15
eISSN - 1435-5205
pISSN - 2213-056X
DOI - 10.18352/lq.10340
Subject(s) - favipiravir , lopinavir , pandemic , covid-19 , medicine , public health , hydroxychloroquine , ritonavir , family medicine , disease , human immunodeficiency virus (hiv) , infectious disease (medical specialty) , viral load , nursing , antiretroviral therapy
The coronavirus 2019 (COVID-19) disease has affected millions of lives, forcing most of us to stay at home and work. However, there is an immediate need to conduct research on potential drugs against COVID-19. In this article, the extent to which major publishers have provided access for the public to read research articles relevant to potential drug candidates for the COVID-19 disease are presented. A systematic search of five electronic databases (Elsevier’s ScienceDirect, Taylor & Francis, SpringerLink, Wiley, and New England Journal of Medicine (NEJM)) was conducted on April 12-17, 2020. The total number of research articles containing terms ‘Ribavirin’, ‘Remdesivir’, ‘Hydroxychloroquine OR Chloroquine’, ‘Favipiravir’, ‘Lopinavir OR Ritonavir’, ‘Sarilumab’, and ‘Tocilizumab’, available for the public to read for free were determined. In this study, there was a lack of full access to research articles related to potential drugs of COVID-19 in commercial academic databases, except for ‘Remdesivir’ and ‘Favipiravir’ from NEJM.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom